Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Sep 24, 2019- Data includes an oral presentation from full advanced endometrial carcinoma (EC) cohort of Phase 1b/2 study of KEYTRUDA plus LENVIMAEisai today announced the presentation of new data and analyses via one oral proffered paper presentation, four poster discussions and seven poster presentations at the 2019 European Society for...
-
Sep 17, 2019Combination Treatment Approved for Patients with Advanced Endometrial Carcinoma That Is Not Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR), Who Have Disease Progression Following Prior Systemic Therapy and Are Not Candidates for Curative Surgery or Radiation
KENILWORTH, N.J., and WOODCLIFF LAKE, N.J., Sept. 17, 2019 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced that the U.S. Food and Drug...
-
Jul 23, 2019Designation Granted for Potential First-Line Treatment of Patients with Advanced Unresectable Hepatocellular Carcinoma Not Amenable to Locoregional Treatment
Kenilworth, N.J., and Woodcliff Lake, N.J., July 23, 2019 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced that the U.S. Food and Drug...
- Jun 4, 2019- Targeting CXCR4 May Impact Aggressive Metastatic Behavior of Cancer Cells, Which May be Related to a Poor Prognosis
Eisai today announced additional data from an ongoing Phase 1 trial exploring the investigational combination of eribulin and balixafortide, a CXCR4 antagonist, in patients with HER2-negative...
-
May 16, 2019- Data highlight continued progress on clinical trials for the LENVIMA plus KEYTRUDA combination across multiple tumor types, including endometrial carcinoma (EC), for which the combination was granted U.S. FDA Breakthrough Therapy Designation in July 2018
Eisai today announced the presentation of new data and analyses in one oral presentation, 11 posters at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting from May 31-June 4 in...